Compare NBY & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBY | ALT |
|---|---|---|
| Founded | 2000 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.6M | 421.5M |
| IPO Year | 2007 | 2005 |
| Metric | NBY | ALT |
|---|---|---|
| Price | $1.95 | $3.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 405.9K | ★ 2.6M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.42 | 25.37 |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $370,000.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.57 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $0.43 | $2.87 |
| 52 Week High | $19.95 | $7.73 |
| Indicator | NBY | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 57.82 | 46.77 |
| Support Level | $1.01 | $2.87 |
| Resistance Level | $2.52 | $4.25 |
| Average True Range (ATR) | 0.26 | 0.16 |
| MACD | 0.11 | 0.06 |
| Stochastic Oscillator | 96.45 | 76.87 |
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.